Hjem › Nyrekreft (nyrecellekarcinom) › Ohio › Columbus
Kliniske studier for Nyrekreft (nyrecellekarcinom) i Columbus, OH
13 studier for Nyrekreft (nyrecellekarcinom) søker deltakere på steder i og rundt Columbus (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
- Ohio State University Comprehensive Cancer Center, Columbus
- Mount Carmel East Hospital, Columbus
- The Mark H Zangmeister Center, Columbus
- og 8 flere
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
RekruttererFase 2
- Ohio State University Comprehensive Cancer Center, Columbus
- Mount Carmel East Hospital, Columbus
- Columbus Oncology and Hematology Associates Inc, Columbus
- og 11 flere
Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer
RekruttererFase 2
- Ohio State University Comprehensive Cancer Center, Columbus
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
RekruttererObservasjonsstudie
- The Ohio State University Comprehensive Cancer Center, Columbus
Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC
RekruttererFase 2
- Ohio State University Comprehensive Cancer Center, Columbus
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
RekruttererFase 2
- Ohio State University Comprehensive Cancer Center, Columbus
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
RekruttererFase 3
- Ohio State University Comprehensive Cancer Center, Columbus
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
RekruttererFase 1
- Xencor Investigative Site, Columbus
A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
RekruttererFase 1/2
- James Cancer Hospital and Solove Research Institute, Columbus
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
RekruttererFase 1
- Ohio State University, Columbus
Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
- The Ohio State University Wexner Medical Center, Columbus
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
RekruttererFase 1/2
- The Ohio State University, Columbus
Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial
RekruttererFase 3
- Ohio State University Comprehensive Cancer Center, Columbus
Nyrekreft (nyrecellekarcinom)-studier i andre byer
- Houston, TX35 studier
- New York City, NY27 studier
- Nashville, TN23 studier
- Dallas, TX23 studier
- St. Louis, MO23 studier
- Los Angeles, CA20 studier
- Boston, MA16 studier
- Baldwin Park, CA16 studier
- Philadelphia, PA15 studier
- Pittsburgh, PA15 studier
- Queens, NY15 studier
- Rochester, MN14 studier
Andre studier i Columbus
- Ikke-småcellet lungekreft57 studier
- Brystkreft40 studier
- Eggstokkreft39 studier
- Kreft (alle typer)38 studier
- Lungekreft37 studier
- Akut myelogen leukemi35 studier
- Kronisk lymfatisk leukemi28 studier
- Metastatisk kreft27 studier
- Endometriekreft25 studier
- Prostatakreft24 studier
- Multipelt myelom24 studier
- Kolorektal kreft24 studier
Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.